Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
Weekly Epidemiological and Operational updates
Last update: 23 January 2021
Confirmed cases :: 96 877 399 [week ago: 92 506 811] [two weeks ago: 87 589 206]
Confirmed deaths :: 2 098 879 [week ago: 2 001 773] [two weeks ago: 1 906 606]
Countries, areas or territories with cases :: 224
19 January 2021
Weekly epidemiological update – 19 January 2021
Globally, 4.7 million new cases were reported in the past week, a decline of 6% from last week, and the number of new deaths has climbed to a record high at 93 000, a 9% increase from last week. This brings the cumulative numbers to over 93 million reported cases and over 2 million deaths globally since the start of the pandemic.
In this edition of the COVID-19 Weekly Epidemiological Update, special focus updates are provided on: Children, COVID-19, and transmission in schools, as well as on SARS-CoV-2 variants of concern.
COVID – COVAX
COVAX announces new agreement, plans for first deliveries
:: COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements
:: Additionally, COVAX announced that, pending WHO emergency use listings, nearly 150 million doses of the AstraZeneca/Oxford candidate are anticipated to be available in Q1 2021, via existing agreements with the Serum Institute of India (SII) and AstraZeneca
:: COVAX is therefore on track to deliver at least 2 billion doses by the end of the year, including at least 1.3 billion doses to 92 lower income economies in the Gavi COVAX AMC
:: Click here for the latest COVAX supply forecast
Geneva/Oslo 22 January 2021 – COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO Emergency Use Listing. Rollout will commence with the successful negotiation and execution of supply agreements.
In further support of its mission to expedite early availability of vaccines to lower-income countries and help bring a rapid end to the acute stage of the COVID-19 pandemic, COVAX also confirmed today that it will exercise an option – via an existing agreement with Serum Institute of India (SII) – to receive its first 100 million doses of the AstraZeneca/Oxford University-developed vaccine manufactured by SII.
Of these first 100 million doses, the majority are earmarked for delivery in the first quarter of the year, pending WHO Emergency Use Listing. The WHO review process, which is currently underway, follows approval for restricted use in emergency situations by the Drugs Controller General of India earlier this month, and is a critical aspect of ensuring that any vaccine procured through COVAX is fully quality assured. According to the latest WHO update, a decision on this vaccine candidate is anticipated in the middle of February at the earliest…
COVAX now has agreements in place to access just over two billion doses of several promising vaccine candidates. Negotiations continue for further doses to be secured through existing R&D agreements by COVAX co-lead the Coalition for Epidemic Preparedness Innovations (CEPI), through evaluations of new products with promising results and through contributions from donors.
Based on this, COVAX anticipates being able to provide participating economies doses of safe and effective vaccines – enough to protect health care and other frontline workers as well as some high-risk individuals – beginning in Q1 2021. The aim is to protect at least 20% of each participating population by the end of the year – unless a participant has requested a lower percentage of doses. At least 1.3 billion of these doses will be made available to the 92 economies eligible for the Gavi COVAX AMC by the end of 2021…